ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, received an Award of Excellence from Genzyme.

The award recognizes ChemPartner's outstanding performance and valued contributions to the Genzyme-ChemPartner collaboration over the past almost three years. The collaboration has contributed to Genzyme's success in a number of early discovery programs. ChemPartner has consistently met and exceeded Genzyme's expectations by providing high-quality science, efficient project management and effective communication.

Dr. Jim Burns, SVP of Drug and Biomaterial Discovery and Development at Genzyme, commented, ?It is our long-term strategy to partner with the best CROs in supporting our drug R&D programs. In so doing, our internal drug R&D resources can be used more effectively across multiple programs. ChemPartner has proven its capabilities and effectiveness during almost three years of working with us and has become our preferred choice for a chemistry contract research organization.?

Michael Hui, founder and CEO of ShangPharma, added, "We are honored to receive this award and appreciate Genzyme's recognition of the efforts and dedication of our talented team of scientists. This award reflects the value and capabilities of ChemPartner's service to our partners."

ABOUT GENZYME

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

ShangPharma Corporation
Lan Xie, VP of Finance and Operations
IR@shangpharma.com
or
Christensen
In New York
Kimberly Minarovich, +1-917-533-3268
kminarovich@christensenir.com
or
In Hong Kong
Tip Fleming, +852-9212-0684
tfleming@christensenir.com